Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Poxel Reports Financial Results for First Half 2020 and Provides a Corporate Update

share with twitter share with LinkedIn share with facebook
09/16/2020 | 09:54am EDT

LYON - POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today reported its financial results for the period ended June 30, 2020 and provided a corporate update.

'Through September, we accomplished several important corporate and clinical objectives, including strengthening our financial position through multiple financial sources including the drawdown of the IPF loan of EUR 10 million in March, a capital raise of EUR 17.7 million in May and a subsequent milestone payment of EUR 4 million during the third quarter from our partner Sumitomo Dainippon Pharma for the Imeglimin J-NDA submission,' said Thomas Kuhn, CEO of Poxel. 'We also continued to make solid progress with our development programs. We reported positive results from preclinical and clinical studies for PXL770 and are continuing to evaluate broader metabolic diseases, including chronic and rare diseases, for our AMPK activation and D-TZD platforms.'

'From an execution standpoint in the context of the COVID-19 pandemic, I am very pleased to report that we recently initiated the Phase 2 trial for PXL065 in biopsy-proven NASH patients across multiple clinical sites in the U.S.,' continued Thomas Kuhn, CEO of Poxel. 'This is a streamlined development program with a single Phase 2 trial given the knowledge of pioglitazone, including data in NASH, and the 505(b)(2) regulatory pathway. Based on pioglitazone's known efficacy and safety results in NASH, its cardiovascular benefits combined with the exciting PXL065 results to-date, we believe that PXL065 has the potential to produce compelling results and become a leading oral drug candidate in development for this important unmet medical need.'

'For the remainder of 2020, we expect several important upcoming milestones and events, including the PXL770 Phase 2a efficacy and safety results in approximately 100 likely-NASH patients around the end of September 2020, finalization of the Imeglimin Phase 3 plan in the U.S. by Metavant, additional preclinical data related to our AMPK and D-TZD platforms and presentations for Imeglimin, PXL770 and PXL065 at several scientific meetings and published results in peer-reviewed scientific journals,' added Thomas Kuhn.

About Poxel SA

Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel's first-in-class lead product, targets mitochondrial dysfunction. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. A Japanese new drug application (J-NDA) is under review by the Pharmaceuticals and Medical Devices Agency (PMDA) to request approval for the manufacturing and marketing of Imeglimin for the treatment of type 2 diabetes. Poxel also established a partnership with Roivant Sciences for Imeglimin's development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a MPC inhibitor, is in a single Phase 2 clinical trial for the treatment of NASH. Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business.

As of the date of this press release, and based on publicly available information, the Company has not identified the occurrence of any material negative effect on its business due to the COVID-19 pandemic that remains unresolved. However, the Company anticipates that the COVID-19 pandemic could have further material negative impact on its business operations. The worldwide impact of COVID-19 may notably affect the Company's internal organization and efficiency, particularly in countries where it operates and where confinement measures are implemented by the authorities. In addition, COVID-19 may impact market conditions and the Company's ability to seek additional funding or enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in the initiation or the timing of results of preclinical and/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company's development programs and partnered programs. The Company will continue to actively monitor the situation.

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.


Jonae R. Barnes

Tel: +1 617 818 2985

Email: jonae.barnes@poxelpharma.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
POXEL -2.44% 6 Real-time Quote.-49.59%
SUMITOMO CHEMICAL COMPANY, LIMITED -2.48% 354 End-of-day quote.-28.92%
SUMITOMO DAINIPPON PHARMA CO., LTD. -2.50% 1208 End-of-day quote.-43.29%
share with twitter share with LinkedIn share with facebook
All news about POXEL
12:46pPOXEL : Announces Participation at Several Upcoming Scientific and Investor Conf..
10/21Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Qu..
10/20POXEL : Corporate Presentation - English
10/20POXEL : Provides Corporate Update and Reports Cash and Revenue for the Third Qua..
10/16Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the Frenc..
10/15POXEL : Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French..
10/11POXEL : Corporate Presentation - English
10/07POXEL : Corporate Presentation - English
10/02POXEL : Announces Positive Results from Phase 2a NASH Trial with PXL770, an Oral..
10/01POXEL : Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral..
More news
Sales 2020 14,7 M 17,4 M 17,4 M
Net income 2020 -28,0 M -33,1 M -33,1 M
Net cash 2020 21,6 M 25,5 M 25,5 M
P/E ratio 2020 -5,90x
Yield 2020 -
Capitalization 175 M 207 M 206 M
EV / Sales 2020 10,4x
EV / Sales 2021 2,55x
Nbr of Employees 51
Free-Float 75,3%
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 4
Average target price 18,55 €
Last Close Price 6,15 €
Spread / Highest target 241%
Spread / Average Target 202%
Spread / Lowest Target 168%
EPS Revisions
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Sebastien Bolze Chief Operating Officer & Executive Vice President
Anne Renevot Chief Financial Officer & Executive Vice President
Sophie Hallakou-Bozec Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.64.97%37 810
BEIGENE, LTD.81.76%27 304